6.75
-0.44(-6.12%)
Currency In USD
| Previous Close | 7.19 |
| Open | 7.3 |
| Day High | 7.35 |
| Day Low | 6.61 |
| 52-Week High | 8.36 |
| 52-Week Low | 2.2 |
| Volume | 70,313 |
| Average Volume | 1.06M |
| Market Cap | 26.62M |
| PE | -0.7 |
| EPS | -9.67 |
| Moving Average 50 Days | 5.48 |
| Moving Average 200 Days | 4.03 |
| Change | -0.44 |
Data not available
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”
GlobeNewswire Inc.
Jan 09, 2026 12:00 PM GMT
New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovationBOTHELL, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (N
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
GlobeNewswire Inc.
Dec 18, 2025 12:02 PM GMT
Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors an
Athira Pharma Announces Reverse Stock Split
GlobeNewswire Inc.
Sep 11, 2025 1:00 PM GMT
BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, t